-
Hematol Oncol: Differential expression of estrogen receptor-alpha in follicle tree cells in patients with level 1-2 and level 3 follicular lymphoma
Time of Update: 2020-07-14
Hormone therapy has been used in patients with estrogen receptor alpha (ER alpha) positive breast cancer Recently, a number of studies have reported on the expression of ER alpha in tumor cells B
-
cell carcinoma, and two high-level international studies have led PD-1 inhibitors
Time of Update: 2022-11-15
On November 1, the innovative PD-1 inhibitor sylplulimab (trade name: Hans-form ®) combined with chemotherapy (carboplatin and albumin paclitaxel) independently developed by China was approved for the
-
High-level evidence, reviewed in the literature, answers to multiple endocrine neoplasia type 1
Time of Update: 2022-10-21
Cross-sectional and functional imaging as the lowest consensus statement for diagnostic and follow-up methods of DP-NENs Detection, size detection, assessment of progression and presence of metastatic disease of DP-NENs are key elements in managing MEN1 patients to determine appropriate treatment strategies.
-
German natural gas operator: "North Stream-1" is only at the pre-maintenance level even if the gas supply is restored
Time of Update: 2022-10-04
The German natural gas operator said on the 20th that the 10-day routine maintenance work of the "North Stream-1" pipeline will end at 6:00 local time on the 21st, and it is estimated that the gas transmission volume will be consistent with the level before the routine maintenance .
-
Front Immunol: The use of gliptin reduces SDF-1/CXCL12 levels in patients with bullous pemphigoid
Time of Update: 2022-10-02
Figure 1 IgG autoantibodies against BP180 NC16A domain and full-length BP 180 in serum samples of T2D patients using (+g) or without gliptin.
Figure 1 IgG autoantibodies against BP180 NC16A domain and full-length BP 180 in serum samples of T2D patients using (+g) or without gliptin.
-
Neurology: Changes in peripheral neurofilament light (NFL) levels may be an effective biomarker
Time of Update: 2022-05-26
Recently, a study published in Neurology hypothesized that NFL levels in SCA1 could serve as (1) a peripheral biomarker close to the onset of clinical ataxia, (2) early neuronal decline in the pre-ataxia phase, and (3) Objective trial outcome variables, allowing reduction of the sample size required in treatment trials .
-
JAMA Netw Open: Correlation between plasma EBV DNA levels and prognosis in patients with recurrent
Time of Update: 2022-04-23
Studies have shown that plasma EBV DNA is a prognostic marker in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) receiving anti-PD-1 monotherapy and can be used to monitor disease progression .
-
J Int AIDS Soc: Estimates of Population-Level HIV-1 Incidence by Cross-sectional Incidence Analysis in the HPTN 071 (PopART) Trial
Time of Update: 2022-01-22
We compared the accuracy of the multiple-trial algorithm (MAA) with the incidence estimates observed in the community-randomized HPTN 071 (PopART) trial, in which the majority of HIV-infected participants were virally suppressed .
-
JCEM: Correlation between HbA1c levels and adverse pregnancy outcomes in patients with type 1 diabetes
Time of Update: 2021-11-12
Although the metabolic balance of type 1 diabetes (T1D) patients during pregnancy is optimized, maternal-fetal complications are still higher than those of the general population .
Elevated HbA1c levels are related to maternal-fetal complications .
-
Cansino new crown vaccine: 2 doses of inactivated and 1 dose of inhalation, the level of neutralizing antibodies increased by up to 300 times
Time of Update: 2021-11-05
The speech was divided into four chapters, including the overall overview of global new crown vaccine research and development, the research and development results and clinical research progress of Cansino adenovirus vector new crown vaccine, the interpretation of clinical data of Keweisha® booster immunization, and the immunization of Keweisha® inhaled dosage form Mechanism and advantages .
-
Diabetologia: Flash monitor is associated with improvement of glycosylated hemoglobin level and DKA rate in patients with type 1 diabetes
Time of Update: 2021-10-20
We assessed the actual impact of the use of the flash monitor (FM) on the levels of HbA1c, diabetic ketoacidosis (DKA) and severe hospitalized hypoglycemia (SHH) in Scottish type 1 diabetic patients, as well as this population The incidence of severe hypoglycemia in different social and demographic strata in China .
-
Daqing Oilfield harvests billion-ton-level shale oilfield to produce 1 million tons in 2022
Time of Update: 2021-09-13
According to the 21st Century Business Herald reporter, Daqing Oilfield is taking Gulong shale oil as an important strategic area, fully implementing the new development concept, and speeding up various tasks .
-
Significantly reduce the level of tau protein AD antisense oligonucleotide therapy announced Phase 1 clinical data
Time of Update: 2021-08-05
In patients treated with BIIB080, 8 weeks after the last dose (day 141), the total tau protein concentration in the cerebrospinal fluid showed a dose-dependent decrease.
In patients treated with BIIB080, the total tau protein level in the cerebrospinal fluid continued to decrease 16 weeks after the last dose.
-
Has the pork price bottomed out from Level 3 to Level 1 warning?
Time of Update: 2021-08-03
On July 12, the reporter visited the vegetable markets and supermarkets in Chengdu and found that the prices of freshwater fish such as silver carp, grass carp, crucian carp, and sea bass currently on the market were still at a high level, but they had fallen back compared to 10 days ago .
-
Lancet: New dual GIP and GLP-1 receptor agonist monotherapy can significantly improve diabetes blood glucose and weight levels
Time of Update: 2021-08-01
In this year's virtual seminar, the results of the GIP/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes who cannot be adequately controlled by diet and exercise alone were announced in the results of the SURPASS-1 and SURPASS-2 trials .